Dimethoxyphenylalkylamine activators of serotonin receptors
AssigneeAtai Therapeutics, Inc.
InventorsGlenn Short, Robert B. Perni, Benjamin Robert Difrancesco, Tanweer A. Khan
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.
Claims11
A method of treating a mental health disease or disorder, the method comprising administering a therapeutically effective amount of a compound of Formula (II-B):
- or a pharmaceutically acceptable salt thereof, wherein,
- R1 is independently at each position hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl;
- R2 and R3 are independently hydrogen, heterocycle, C1-C6 alkyl, C1-C6 haloalkyl, halogen, cyano, OR1, S(O)(=NH) R1, S(O)2R1, S(O)R1 or SR1, wherein at least one of R2 and R3 is hydrogen;
- R4 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, halogen, cyano, OR1, SR1, (C═O)(R14), O(C═O)(R14), NO2, or NH (C═O)(R14), wherein R14 is C1-C6 alkyl, OH, or OC1-C6 alkyl;
- and
- R5 is halogen.
Dependencies are inferred from the claim text.